APAC digital health venture funding stalls at $244m despite $2.65b headline

Consumer-facing categories drew less than $20m in true venture funding.

Asia Pacific's digital health sector pulled in $2.65b in the first quarter of 2026 — but the actual venture capital picture was just $244m across 25 deals, according to Galen Growth's report.

The gap — roughly 11 times larger on the strategic side — marks what analysts describe as a market in transition, moving from innovation-led growth to infrastructure-led consolidation.

Two transactions dominated the quarter as South Korea's Rznomics secured a licensing collaboration with Eli Lilly, potentially worth up to $1.3b.

Meanwhile, US-listed Hims & Hers acquired Australia's Eucalyptus, the country's largest direct-to-consumer telehealth platform, for up to $1.15b, absorbing it into a global operation spanning the UK, Germany, Japan, and Canada.

Within the venture layer, 18 deals had disclosed amounts averaging $13.5m each. Australia led with roughly $91m across five deals, followed by India at $70m across seven deals, and China at $58m across four deals.

South Korea, despite the headline Rznomics deal, contributed only $13m in venture funding. Japan followed at $11m.

Medical imaging attracted the most venture capital of any single category at $57m across four deals. Health insurance and payer infrastructure followed at $41m, then healthcare operations and workflow at $33m, omics research at $29m, and drug discovery at $29m.

Consumer-facing categories — teleconsultation, digital therapeutics, and integrated solutions — together drew less than $20m in true venture funding for the entire quarter.

The report noted investors are not chasing user growth but are backing tools that make fragmented health systems function.

“In a region where provider shortages are acute, and care pathways remain disjointed, the most fundable companies are those solving system-level problems, not consumer-facing ones.”